Skip to main content
. Author manuscript; available in PMC: 2022 Jun 4.
Published in final edited form as: J Drug Target. 2021 Feb 1;29(7):754–760. doi: 10.1080/1061186X.2021.1878364

Figure 1.

Figure 1.

Liposomal delivery of TLR agonists increases levels of activation markers in myeloid cells. Murine bone marrow cells were treated with PBS, C3-liposomes with 3 TLR agonists, or control-liposomes with 3 TLR agonists for 24 h before analysis by flow cytometry. Data are expressed as mean ± standard error (n = 3). *p Value < .05, compared to PBS. Bracket indicates significant difference between C3-liposomes and control-liposomes.